Department of Gastroenterology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Department of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, 247-8533, Japan.
J Transl Med. 2023 Jun 19;21(1):398. doi: 10.1186/s12967-023-04226-z.
Myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease (ME/CFS/SEID) is a condition diagnosed primarily based on clinical symptoms, including prolonged fatigue and post-exertional malaise; however, there is no specific test for the disease. Additionally, diagnosis can be challenging since healthcare professionals may lack sufficient knowledge about the disease. Prior studies have shown that patients with ME/CFS/SEID have low serum acylcarnitine levels, which may serve as a surrogate test for patients suspected of having this disease. This systematic review and meta-analysis aimed to investigate the differences in serum acylcarnitine levels between patients with ME/CFS/SEID and healthy controls.
This systematic review was conducted using PubMed and Ichushi-Web databases. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, we included all studies from the databases' inception until February 17, 2023, that evaluated blood tests in both patients with ME/CFS/SEID and healthy control groups. The primary endpoint was the difference in serum acylcarnitine levels between the two groups.
The electronic search identified 276 studies. Among them, seven met the eligibility criteria. The serum acylcarnitine levels were analyzed in 403 patients with ME/CFS/SEID. The patient group had significantly lower serum acylcarnitine levels when compared with the control group, and the statistical heterogeneity was high.
The patient group had significantly lower serum acylcarnitine levels when compared with the control group. In the future, the measurement of serum acylcarnitine levels, in addition to clinical symptoms, may prove to be a valuable diagnostic tool for this condition.
肌痛性脑脊髓炎/慢性疲劳综合征/全身性劳累不耐受疾病（ME/CFS/SEID）是一种主要基于临床症状诊断的疾病，包括长时间疲劳和劳累后不适；然而，目前尚无针对该疾病的特定检测方法。此外，由于医疗保健专业人员对该疾病的了解可能不足，因此诊断可能具有挑战性。先前的研究表明，ME/CFS/SEID 患者的血清酰基辅酶 A 水平较低，这可能是疑似患有该疾病的患者的替代检测方法。本系统评价和荟萃分析旨在研究 ME/CFS/SEID 患者与健康对照组之间血清酰基辅酶 A 水平的差异。
本系统评价使用 PubMed 和 Ichushi-Web 数据库进行。根据系统评价和荟萃分析的首选报告项目声明，我们纳入了数据库成立以来至 2023 年 2 月 17 日的所有研究，这些研究评估了 ME/CFS/SEID 患者和健康对照组的血液检测。主要终点是两组之间血清酰基辅酶 A 水平的差异。
电子检索共确定了 276 项研究。其中，有 7 项符合纳入标准。对 403 名 ME/CFS/SEID 患者进行了血清酰基辅酶 A 水平分析。与对照组相比，患者组的血清酰基辅酶 A 水平显著降低，且存在高度统计学异质性。
与对照组相比，患者组的血清酰基辅酶 A 水平显著降低。未来，除了临床症状外，血清酰基辅酶 A 水平的测量可能成为该疾病有价值的诊断工具。
